Capsule Summary Slidesets

Share

Program Content

Activities

CheckMate 8HW
CheckMate 8HW: Interim Analysis of Phase III Trial of Nivolumab + Ipilimumab vs Nivolumab for MSI-H or dMMR mCRC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 04, 2025

Expires: August 03, 2025

STARTER NET
STARTER-NET: Phase III Study of Everolimus ± Lanreotide for Unresectable or Recurrent GEP-NET
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 04, 2025

Expires: August 03, 2025

ACCELERATE
ACCELERATE: Phase III Study of Adjuvant Chemotherapy ± Chemoradiation in Gallbladder Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 04, 2025

Expires: August 03, 2025

Botensilimab and Balstilimab for MSS mCRC
Botensilimab ± Balstilimab for Refractory Microsatellite-Stable Metastatic Colorectal Cancer Without Liver Metastases
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 04, 2025

Expires: August 03, 2025

BREAKWATER
BREAKWATER: Phase III Study of First-line Encorafenib + Cetuximab + Chemotherapy vs SoC for BRAF V600E–Mutant mCRC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 04, 2025

Expires: August 03, 2025

MAIC of 177LuDOTATATE vs Sunitinib
177Lu-DOTATATE vs Sunitinib as Initial Treatment for Advanced Grade 2 Pancreatic Neuroendocrine Tumors Using Matching-Adjusted Indirect Comparison
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 05, 2025

Expires: August 04, 2025

CABINET Subgroup Analysis
CABINET: Subgroup Analysis of Cabozantinib vs Placebo After ≥1 Prior Line of Therapy in Advanced Extrapancreatic Neuroendocrine Tumors Arising in GI Tract
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 07, 2025

Expires: August 06, 2025

WW vs TME After TNT for Rectal Cancer
CAO/ARO/AIO-12 and OPRA: Pooled Analysis of Watch and Wait vs Total Mesorectal Excision in Patients With Rectal Cancer Who Respond to Total Neoadjuvant Therapy
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 07, 2025

Expires: August 06, 2025

Provided by

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Exelixis, Inc., and Novartis Pharmaceuticals Corporation.

Boehringer Ingelheim Pharmaceuticals, Inc.

Exelixis, Inc.

Novartis Pharmaceuticals Corporation